The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
ESR1 mutations in breast cancer
Open accessAbstract
The acquisition of ligand‐independent ESR1 mutations during aromatase inhibitor therapy in metastatic estrogen receptor (ER)‐positive breast cancer is a common mechanism of hormonal therapy resistance. Preclinical and clinical studies have demonstrated that ESR1 mutations can preexist in primary tumors and can be enriched during metastasis. Furthermore, ESR1 mutations express a unique transcriptional profile that favors tumor progression, suggesting that selected ESR1 mutations may influence metastasis. Several groups have used sensitive detection methods using patient liquid biopsies to track ESR1 or truncal somatic mutations to predict treatment outcome and tumor progression, and some of these techniques may eventually be used to guide sequential treatment options in patients. Further development and standardization of mutation tracking in circulating tumor DNA is ongoing. Clinically, patients with ESR1 mutations derive clinical benefit when treated with fulvestrant and CDK4/6‐targeted therapies, but the development of more potent selective ER degraders and/or new targeted biotherapies are needed to overcome the endocrine‐resistant phenotype of ESR1 mutant–bearing tumors. In this review, we discuss the mechanisms of resistance and dissemination of ESR1 mutations as well as the detection methods for ESR1 mutation tracking, newly discovered potential therapeutic targets, and the clinical implications and treatment options for treating patients with ESR1 mutant–bearing tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., Rouas, G., Francis, P., Crown, J. P. A., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,632
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Razavi, P., Chang, M. T., Xu, G., Bandlamudi, C., Ross, D. S., Vasan, N., Cai, Y., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.008 · Cited by 996
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770 · cited 1×
“In a separate study, it was demonstrated that systemic CDK4/6 inhibition resulted in suppression of regulatory T cells, but had a lesser effect on CD8+ T cells, suggesting there may be an enhanced T cell– mediated antitumor response.(71) These preclinical data suggest that systemic CDK4/6 inhibition may upregulate PD-…”
BackgroundHerrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722
O'Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., Garcia-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 650
Li, S., Shen, D., Shao, J., Crowder, R., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.022 · Cited by 626
Schiavon, G., Hrebien, S., Garcia-Murillas, I., Cutts, R. J., Pearson, A., Tarazona, N., Fenwick, K., Kozarewa, I., Lopez-Knowles, E., Ribas, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac7551 · Cited by 575
Baselga, J., Im, S.-A., Iwata, H., Cortés, J., De Laurentiis, M., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 533
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response
Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2234 · Cited by 528
Chandarlapaty, S., Chen, D., He, W., Sung, P., Samoila, A., You, D., Bhatt, T., Patel, P., Voi, M., Gnant, M., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1279 · Cited by 494
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2063 · Cited by 488
Kim, S.-B., Dent, R., Im, S.-A., Espié, M., Blau, S., Tan, A. R., Isakoff, S. J., Oliveira, M., Saura, C., Wongchenko, M. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30450-3 · Cited by 478
Liu, S., Lachapelle, J., Leung, S., Gao, D., Foulkes, W. D., & Nielsen, T. O. (2012) · Breast Cancer Research · doi:10.1186/bcr3148 · Cited by 436
Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., & Trepel, J. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7251 · Cited by 423
O’Leary, B., Hrebien, S., Morden, J. P., Beaney, M., Fribbens, C., Huang, X., Liu, Y., Bartlett, C. H., Koehler, M., Cristofanilli, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03215-x · Cited by 414
Hidalgo, M., Bruckheimer, E., Rajeshkumar, N. V., Garrido-Laguna, I., De Oliveira, E., Rubio-Viqueira, B., Strawn, S., Wick, M. J., Martell, J., & Sidransky, D. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0233 · Cited by 406
Condorelli, R., Spring, L., O’Shaughnessy, J., Lacroix, L., Bailleux, C., Scott, V., Dubois, J., Nagy, R. J., Lanman, R. B., Iafrate, A. J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx784 · Cited by 394
Merenbakh-Lamin, K., Ben-Baruch, N., Yeheskel, A., Dvir, A., Soussan-Gutman, L., Jeselsohn, R., Yelensky, R., Brown, M., Miller, V. A., Sarid, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1197 · Cited by 393
Di Leo, A., Johnston, S., Lee, K. S., Ciruelos, E., Lønning, P. E., Janni, W., O'Regan, R., Mouret-Reynier, M.-A., Kalev, D., Egle, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30688-5 · Cited by 381
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
Toy, W., Weir, H., Razavi, P., Lawson, M., Goeppert, A. U., Mazzola, A. M., Smith, A., Wilson, J., Morrow, C., Wong, W. L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1523 · Cited by 368
Spoerke, J. M., Gendreau, S., Walter, K., Qiu, J., Wilson, T. R., Savage, H., Aimi, J., Derynck, M. K., Chen, M., Chan, I. T., et al. (2016) · Nature Communications · doi:10.1038/ncomms11579 · Cited by 309
Krop, I. E., Mayer, I. A., Ganju, V., Dickler, M., Johnston, S., Morales, S., Yardley, D. A., Melichar, B., Forero-Torres, A., Lee, S. C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00106-6 · Cited by 295
Zhang, Q., Borg, Å., Wolf, D. M., Oesterreich, S., & Fuqua, S. A. W. (1997) · PubMed · Cited by 291
Self-citationChen, D., Riedl, T., Washbrook, E., Pace, P. E., Coombes, R. C., Egly, J.-M., & Ali, S. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00004-3 · Cited by 290
Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations
Jeselsohn, R., Bergholz, J. S., Pun, M., Cornwell, M., Liu, W., Nardone, A., Xiao, T., Li, W., Qiu, X., Buchwalter, G., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.004 · Cited by 276
Personalized Cancer Medicine: An Organoid Approach
Aboulkheyr Es, H., Montazeri, L., Aref, A. R., Vosough, M., & Baharvand, H. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2017.12.005 · Cited by 275
Johnston, S. R., Kilburn, L. S., Ellis, P., Dodwell, D., Cameron, D., Hayward, L., Im, Y.-H., Braybrooke, J. P., Brunt, A. M., Cheung, K.-L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70322-x · Cited by 274
Jansen, V. M., Bhola, N. E., Bauer, J. A., Formisano, L., Lee, K.-M., Hutchinson, K. E., Witkiewicz, A. K., Moore, P. D., Estrada, M. V., Sánchez, V., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2653 · Cited by 244
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions.
Fuqua, S. A. W., Wiltschke, C., ZHANG, Q. X., Borg, Å., Castles, C. G., Friedrichs, W. E., Hopp, T., Hilsenbeck, S. G., Mohsin, S. K., O'Connell, P., et al. (2000) · PubMed · Cited by 234
Self-citationShaw, J. A., Guttery, D. S., Hills, A., Fernandez-Garcia, D., Page, K., Rosales, B. M., Goddard, K. S., Hastings, R. K., Luo, J., Ogle, O., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0825 · Cited by 222
Nanda, R., Liu, M. C., Yau, C., Asare, S., Hylton, N., Veer, L. V., Perlmutter, J., Wallace, A. M., Chien, A. J., Forero-Torres, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.506 · Cited by 204
Wang, P., Bahreini, A., Gyanchandani, R., Lucas, P. C., Hartmaier, R. J., Watters, R. J., Jonnalagadda, A. R., Trejo Bittar, H. E., Berg, A., Hamilton, R. L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1534 · Cited by 202
Kornblum, N., Zhao, F., Manola, J., Klein, P., Ramaswamy, B., Brufsky, A., Stella, P. J., Burnette, B., Telli, M., Makower, D. F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9331 · Cited by 189
Harrod, A., Fulton, J., Nguyen, V. T. M., Periyasamy, M., Ramos-Garcia, L., Lai, C.-F., Metodieva, G., de Giorgio, A., Williams, R. L., Santos, D. B., et al. (2017) · Oncogene · doi:10.1038/onc.2016.382 · Cited by 182
Weir, H. M., Bradbury, R. H., Lawson, M., Rabow, A. A., Buttar, D., Callis, R. J., Curwen, J. O., de Almeida, C., Ballard, P., Hulse, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2357 · Cited by 175
Fribbens, C., Garcia Murillas, I., Beaney, M., Hrebien, S., O’Leary, B., Kilburn, L., Howarth, K., Epstein, M., Green, E., Rosenfeld, N., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx483 · Cited by 168
Martin, L., Ribas, R., Simigdala, N., Schuster, E. F., Pancholi, S., Tenev, T., Gellert, P., Buluwela, L., Harrod, A., Thornhill, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01864-y · Cited by 164
Garner, F., Shomali, M., Paquin, D., Lyttle, C. R., & Hattersley, G. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000271 · Cited by 162
Malorni, L., Piazza, S., Ciani, Y., Guarducci, C., Bonechi, M., Biagioni, C., Hart, C. D., Verardo, R., Leo, A. D., & Migliaccio, I. (2016) · Oncotarget · doi:10.18632/oncotarget.12010 · Cited by 162
Bihani, T., Patel, H. K., Arlt, H., Tao, N., Jiang, H., Brown, J. L., Purandare, D. M., Hattersley, G., & Garner, F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2561 · Cited by 161
Bahreini, A., Li, Z., Wang, P., Levine, K. M., Tasdemir, N., Cao, L., Weir, H. M., Puhalla, S. L., Davidson, N. E., Stern, A. M., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0851-4 · Cited by 160
Lok, S. W., Whittle, J. R., Vaillant, F., Teh, C. E., Lo, L. L., Policheni, A. N., Bergin, A. R. T., Desai, J., Ftouni, S., Gandolfo, L. C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1151 · Cited by 148
Baselga, J. M., Dent, S. F., Cortés, J., Im, Y., Dieras, V. C., Harbeck, N., Krop, I. E., Verma, S., Wilson, T. R., Jin, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.18_suppl.lba1006 · Cited by 138
MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
de Leeuw, R., McNair, C. M., Schiewer, M. J., Neupane, N. P., Brand, L. J., Augello, M. A., Li, Z., Cheng, L. C., Yoshida, A., Courtney, S. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0410 · Cited by 131
Joseph, J. D., Darimont, B. D., Zhou, W. J., Arrazate, A., Young, A. E., Ingalla, E., Walter, K., Blake, R. A., Nonomiya, J., Guan, Z., et al. (2016) · eLife · doi:10.7554/elife.15828 · Cited by 126
Clatot, F., Perdrix, A., Augusto, L., Beaussire, L., Delacour, J., Calbrix, C., Sefrioui, D., Viailly, P., Bubenheim, M., Moldovan, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12950 · Cited by 106
Yeruva, S. L. H., Zhao, F., Miller, K. D., Tevaarwerk, A. J., Wagner, L. I., Gray, R. J., Sparano, J. A., & Connolly, R. M. (2018) · npj Breast Cancer · doi:10.1038/s41523-017-0053-3 · Cited by 100
Ma, C. X., Luo, J. R., Naughton, M., Ademuyiwa, F. O., Suresh, R., Griffith, M., Griffith, O. L., Skidmore, Z. L., Spies, N. C., Ramu, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1745 · Cited by 96
Chung, J., Pavlick, D. C., Hartmaier, R. J., Schrock, A. B., Young, L., Forcier, B., Ye, P., Levin, M. K., Goldberg, M. E., Burris, H. A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx490 · Cited by 87
Min, A., Kim, J. E., Kim, Y., Lim, J. M., Kim, S., Kim, J. W., Lee, K.-H., Kim, T., Oh, D., Bang, Y., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.037 · Cited by 87
Gelsomino, L., Gu, G., Rechoum, Y., Beyer, A. R., Pejerrey, S. M., Tsimelzon, A. I., Wang, T., Huffman, K. E., Ludlow, A. T., Andò, S., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3829-5 · Cited by 86
Self-citationEstrogen receptor (ER) α mutations in breast cancer: hidden in plain sight
Fuqua, S. A. W., Gu, G., & Rechoum, Y. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2847-4 · Cited by 85
Self-citationCristofanilli, M., DeMichele, A. M., Giorgetti, C., Turner, N. C., Slamon, D. J., Im, S., Masuda, N., Verma, S., Loi, S., Colleoni, M. A., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.08.011 · Cited by 76
Ma, C. X., Suman, V. J., Goetz, M. P., Northfelt, D., Burkard, M. E., Ademuyiwa, F. O., Naughton, M., Margenthaler, J. A., Aft, R., Gray, R. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1260 · Cited by 75
Gates, L. A., Gu, G., Chen, Y., Rohira, A. D., Lei, J. T., Hamilton, R. A., Yu, Y., Lonard, D. M., Wang, J., Wang, S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0284-2 · Cited by 73
Self-citationBarone, I., Iacopetta, D., Covington, K. R., Cui, Y., Tsimelzon, A. I., Beyer, A. R., Andò, S., & Fuqua, S. A. W. (2010) · Oncogene · doi:10.1038/onc.2009.520 · Cited by 70
Self-citationPavlin, M., Spinello, A., Pennati, M., Zaffaroni, N., Gobbi, S., Bisi, A., Colombo, G., & Magistrato, A. (2018) · Scientific Reports · doi:10.1038/s41598-017-17364-4 · Cited by 69
Takeshita, T., Yamamoto, Y., Yamamoto‐Ibusuki, M., Inao, T., Sueta, A., Fujiwara, S., Omoto, Y., & Iwase, H. (2015) · Translational research · doi:10.1016/j.trsl.2015.09.003 · Cited by 68
André, F., Ciruelos, E. M., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.010 · Cited by 67
New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons
Wang, L., Guillen, V. S., Sharma, N., Flessa, K., Min, J., Carlson, K. E., Toy, W., Braqi, S., Katzenellenbogen, B. S., Katzenellenbogen, J. A., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00106 · Cited by 61
Mao, C., Livezey, M. R., Kim, J. E., & Shapiro, D. J. (2016) · Scientific Reports · doi:10.1038/srep34753 · Cited by 58
Allouchery, V., Beaussire, L., Perdrix, A., Sefrioui, D., Augusto, L., Guillemet, C., Sarafan‐Vasseur, N., Fiore, F. D., & Clatot, F. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0968-0 · Cited by 56
Takeshita, T., Yamamoto, Y., Yamamoto‐Ibusuki, M., Tomiguchi, M., Sueta, A., Murakami, K., Omoto, Y., & Iwase, H. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.07.004 · Cited by 45
Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells
Li, Z., Levine, K. M., Bahreini, A., Wang, P., Chu, D. T. W., Park, B. H., Oesterreich, S., & Lee, A. V. (2017) · Endocrinology · doi:10.1210/en.2017-00693 · Cited by 43
Ladd, B., Mazzola, A. M., Bihani, T., Lai, Z., Bradford, J. R., Collins, M. P., Barry, E., Goeppert, A. U., Weir, H. M., Hearne, K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10852 · Cited by 31
Xu, L., Briaux, A., Becette, V., Benoist, C., Boulai, A., Chemlali, W., Schnitzler, A., Baulande, S., Rivera, S., Mouret‐Reynier, M., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0670-9 · Cited by 31
Yardley, D. A., Ismail-Khan, R. R., & Klein, P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.27_suppl.268 · Cited by 24
Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer
Kimura, M., Hanamura, T., Tsuboi, K., Kaneko, Y., Yamaguchi, Y., Niwa, T., Narui, K., Endo, I., & Hayashi, S. (2018) · Oncotarget · doi:10.18632/oncotarget.25133 · Cited by 15
Cited by
A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer
Clusan, L., Ferrière, F., Flouriot, G., & Pakdel, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076834 · Cited by 382
Liquid biopsies: Potential and challenges
Heidrich, I., Ačkar, L., Mossahebi Mohammadi, P., & Pantel, K. (2021) · International Journal of Cancer · doi:10.1002/ijc.33217 · Cited by 278
Targeting Breast Cancer: An Overlook on Current Strategies
Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M., & Catalano, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043643 · Cited by 88
Metadata
- Authors
- Dustin, D., Gu, G., & Fuqua, S. A. W.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2019-07-18
- Volume
- 125
- Issue
- 21
- Pages
- 3714-3728
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2958196506
- Cited by
- 306
- References
- 79
- FWCI
- 14.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.